Ginkgo Results Presentation Deck

Zymergen and Bayer transactions expected to be valuable platform additions Transactions build on our successful history of opportunistic M&A and technology acquisition integrations Zymergen Integration of Zymergen's automation and technical capabilities is expected to improve Ginkgo's platform capabilities across verticals • Technology fits well into Ginkgo's roadmap and is expected to drive efficiency for customer programs • Zymergen plans to continue its ongoing standalone optimization plans, and Ginkgo will support Zymergen's efforts to realize value from its product portfolio All-stock transaction implied $300M market cap at signing (¹) ● 0.9179x exchange ratio fixed at signing implied 5.25% pro forma ownership by Zymergen shareholders post-transaction • Expected to close by Q1 2023 READ MORE (1) Based on Ginkgo's closing price on Friday, July 22, 2022 (2) Ginkgo owns 70% of Cooksonial Bayer Bayer transaction expected to open up agricultural biologicals market and contribute significant new capabilities West Sacramento Joyn Dissolution New Bayer Collaboration Ginkgo Receives WesSac facility, strain collection, team Platform assets from Joyn and royalty on Bayer net sales of NFix product via Cooksonia (2) Bayer Receives READ MORE $83M consideration NFix program and certain IP rights from Joyn 3 year collaboration with Bayer to advance multiple programs • Ginkgo's largest ever cell programming contract (in terms of R&D service fees) • Opportunity for standard royalty-based downstream value 17 Property of Ginkgo Bioworks Q2 2022 UPDATE & BUSINESS REVIEW

View entire presentation